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Abstract
Background: In 2013, the US Preventive Services Task Force (USPSTF) began recommending lung cancer screening
for high risk smokers aged 55–80 years using low-dose computed tomography (CT) scan. In light of these updated
recommendations, there is a need to understand smokers’ knowledge of and experiences with lung cancer
screening in order to inform the design of patient education and tobacco cessation programs. The purpose of this
study is to describe results of a qualitative study examining smokers’ perceptions around lung cancer screening
tests.
Methods: In 2009, prior to the release of the updated USPSTF recommendations, we conducted 12 120-min,
gender-specific focus groups with 105 current smokers in Charlotte, North Carolina and Cincinnati, Ohio. Focus
group facilitators asked participants about their experience with three lung cancer screening tests, including CT
scan, chest x-ray, and sputum cytology. Focus group transcripts were transcribed and qualitatively analyzed using
constant comparative methods.
Results: Participants were 41–67 years-old, with a mean smoking history of 38.9 pack-years. Overall, 34.3% would
meet the USPSTF’s current eligibility criteria for screening. Most participants were unaware of all three lung cancer
screening tests. The few participants who had been screened recalled limited information about the test.
Nevertheless, many participants expressed a strong desire to pursue lung cancer screening. Using the social
ecological model for health promotion, we identified potential barriers to lung cancer screening at the 1) health
care system level (cost of procedure, confusion around results), 2) cultural level (fatalistic beliefs, distrust of medical
system), and 3) individual level (lack of knowledge, denial of risk, concerns about the procedure). Although this
study was conducted prior to the updated USPSTF recommendations, these findings provide a baseline for future
studies examining smokers’ perceptions of lung cancer screening.
Conclusion: We recommend clear and patient-friendly educational tools to improve patient understanding of
screening risks and benefits and the use of best practices to help smokers quit. Further qualitative studies are
needed to assess changes in smokers’ perceptions as lung cancer screening with CT scan becomes more widely
used in community practice.
Keywords: Lung cancer screening, Smokers, Barriers, Patient-provider communication
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Background
Recommendations for lung cancer screening have been
rapidly evolving in the United States [1]. In 2011, the
National Lung Screening Trial (NLST) reported a 20%
decrease in mortality when low-dose computed tomography (CT) was used to screen people who had smoked
at least one pack of cigarettes a day for 30 years and
who were either current smokers or had quit within the
past 15 years [2]. In 2013, the US Preventive Services
Task Force (USPSTF) recommended annual screening
with low-dose CT for adults aged 55–80 years who meet
the NLST smoking history criteria noted above [3]. In
2015, the Centers for Medicare & Medicaid Services
(CMS) approved coverage for the procedure [4].
Prior to these developments, however, a national survey in 2006–2007 found that some primary care physicians were ordering lung cancer screening tests before
any professional organizations began recommending it
[5]. The results of the survey raised concerns about inappropriate lung cancer screening. Among surveyed
physicians, 55% had ordered chest x-rays, 22% had ordered low-dose CT scans, about 5% had ordered sputum
cytology, and 38% did not order lung cancer screening
[5]. Both chest x-rays and sputum cytology still lack sufficient evidence for recommendation by the USPSTF.
To better understand the use of lung cancer screening,
we conducted a two-part study in 2009. In the first part
of the study, we conducted five telephone focus groups
with primary care physicians to identify factors influencing physicians’ decisions around lung cancer screening.
[6]. Influential factors included perceptions of test effectiveness, attitudes toward screening guidelines, practice
experiences, perceptions of patient’s risk, litigation concerns, insurance reimbursement, and patient request. In
the second part of our study, we conducted in-person
focus groups with cigarette smokers to assess their experience with lung cancer screening. The aim of this
paper is to present a qualitative analysis of the focus
groups with smokers in order to better understand
smokers’ knowledge and perceptions around the three
most commonly used lung cancer screening tests: CT
scan, chest x-ray, and sputum cytology. This paper also
presents a number of potential barriers to obtaining lung
cancer screening which were uncovered during analysis.
Although the context for lung cancer screening has
changed since our study was conducted, these results
provide a baseline for future qualitative studies of
smokers’ perceptions about lung cancer screening. The
findings around smokers’ barriers to screening are particularly important given the challenges to lung cancer
screening implementation that researchers and practitioners continue to identify, including patient access and
disparities [7]. As lung cancer screening with low-dose
CT is implemented alongside tobacco cessation initiatives,
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information about smokers’ perceptions of screening will
continue to be critical in guiding the design and implementation of effective screening programs.

Methods
For this study, we conducted 12 approximately 120-min,
in-person focus groups with cigarette smokers—six in
Charlotte, North Carolina, and six in Cincinnati, Ohio.
In accordance with focus group implementation recommendations [8], each group had 8–9 participants, was
limited to either men or women, and was led by a professional focus group moderator of the same sex who
was employed by a marketing research firm. The study
was supported and led by the Centers for Disease
Control and Prevention (CDC) in collaboration with
Research Triangle Institute International (RTI). The institutional review boards of both organizations reviewed
and approved the protocol for the study. The Office of
Management and Budget approved data collection (ICR
200811–0920-003). Participants provided written consent and received $75 for their participation.
Participants

Two companies specializing in conducting focus groups,
AOC Marketing Research in Charlotte and Fields
Research in Cincinnati, used existing databases to recruit
105 smokers (51 women and 54 men) for participation
in this study. All participants met the following inclusion
criteria: aged 40–70 years, current smoker with a history
of smoking at least one pack of cigarettes per day for
20 years, no previous history of cancer or major lung
conditions, English speaker, currently insured, and had a
physical exam within the past 2 years.
Data collection

Moderators used a semi-structured guide (included in
Additional file 1) to facilitate discussion on participants’
perceptions about and use of lung cancer screening tests.
After initial discussion about preventive health care and
health screenings in general, participants were asked:
“Did your doctor ever talk to you about screening tests
for your lungs—that is, screening tests for lung cancer?”
Next, participants were shown pictures of equipment for
CT scans, chest x-rays, and sputum cytology tests. For
each test, participants were asked a series of questions
to determine whether they knew the test could be used
for lung cancer screening, what their doctor had told
them about the test, and whether their doctor had recommended the test for them. In order to determine if a
test was used for screening, the facilitator asked the
following question: "Was the test done as part of your
routine care or check-up?" To identify diagnostic tests,
the facilitator asked: "Did you have that test because of a
particular problem or symptom?" When asking questions
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about CT scans, the facilitators did not name specific
types of CT scans, such as a low-dose CT scans, to prevent
confusion.
At the end of each focus group, the facilitator told participants that the USPSTF currently did not recommend
screening for lung cancer with any test at that time, but
that studies were underway to continue to assess the effectiveness of CT scans. All participants were then given
information about their state’s smoking quitline, as well
as websites for CDC and the National Cancer Institute.

jointly coded five transcripts using the codebook, reaching 83% agreement in assigned codes. Once all transcripts were coded, a team of three researchers created
data matrices to identify and analyze thematic patterns.
Upon completion of analysis, we organized data pertaining to barriers to screening by using a modified version
of the social ecological model for health promotion to
categorize barriers at the health care system, cultural,
and individual levels [11].

Results
Data analysis

Demographics

All focus groups were audio recorded. Our research
team transcribed each focus group, vetted the transcript
against the original audio recording, and entered the
data into a qualitative analysis program, ATLAS.ti
(version 5.6.1). Following the grounded theory approach,
we used the constant comparative method of qualitative
analysis to create and define inductive codes emerging
from the data [9]. We refined the final set of codes after
examining transcripts for new themes and expanding on
existing themes. We developed a detailed codebook that
followed a standard structure [10]. Two researchers

The 105 focus group participants were divided relatively
evenly by sex and study location (Table 1). They ranged
in age from 41 to 67 years old, with more than 60% being younger than age 55 years. Although the majority
were white, 39.0% were African American. Nearly twothirds of participants had attended some college or
more. All participants were current smokers who had
smoked at least 20 pack-years, with one pack-year being
the equivalent of smoking one pack every day for a year.
More than 75% reported smoking at least 30 pack-years.
Overall, 34.3% of participants would meet the current

Table 1 Focus group participants’ demographic characteristics, 2009
Women

Men

Total

Focus group location

Charlotte, North Carolina

Cincinnati, Ohio

Charlotte, North Carolina

Cincinnati, Ohio

All

Number of focus groups

3

3

3

3

12

n (% of group)

n (% of group)

n (% of group)

n (% of group)

n (% of total)

26 (100)

25 (100)

27 (100)

27 (100)

105 (100)

Total participants
Age
41–54

25 (96.2)

9 (36.0)

20 (74.1)

13 (48.1)

67 (63.8)

55–67

1 (3.8)

16 (64.0)

7 (25.9)

14 (51.9)

38 (36.2)

Mean (SD)

49.0 (4.0)

56.4 (5.9)

51.6 (5.5)

55 (6.4)

53.0 (6.3)

White

12 (46.2)

14 (56.0)

16 (59.3)

18 (66.7)

60 (57.1)

African American

12 (46.2)

11 (44.0)

9 (33.3)

9 (33.3)

41 (39.0)

Other

2 (7.7)

0 (0.0)

2 (7.4)

0 (0.0)

4 (3.8)

Race

Education
High school or less

1 (3.8)

12 (48.0)

9 (33.3)

15 (55.6)

37 (35.2)

Some college or more

25 (96.2)

13 (52.0)

18 (66.7)

12 (44.4)

68 (64.8)

< 30

6 (23.1)

5 (20.0)

10 (37.0)

2 (7.4)

23 (21.9)

≥ 30

20 (76.9)

20 (80.0)

17 (63.0)

25 (92.6)

82 (78.1)

Mean (SD)

35.2 (10.2)

38.2 (16.2)

35.5 (15.1)

46.4 (19.5)

38.9 (16.4)

Yes

1 (3.8)

15 (60.0)

6 (22.2)

14 (51.9)

36 (34.3)

No

25 (96.2)

10 (40.0)

21 (77.8)

13 (48.1)

69 (65.7)

Pack-years smoked

NLST-eligible

a

SD Standard deviation
a
Refers to participants who would meet the eligibility criteria for the National Lung Screening Trial (i.e., age ≥ 55 years and pack-years ≥30)
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USPSTF and CMS eligibility criteria for referral for lung
cancer screening with low-dose CT (i.e., at least 55 years
of age and at least 30 pack-years).
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and they’re trying, and they’re actually looking [for
something].”
Chest X-rays

Previous cessation attempts and reasons for relapse

All participants were current smokers, but most reported at least one, and often multiple, previous cessation attempts. Many participants tried to quit smoking
without cessation aids (i.e., “cold turkey”), while others
used an array of methods, ranging from traditional (e.g.,
nicotine gum/patches, prescription drugs) to less conventional (e.g., hypnosis, acupuncture). Participants’ reasons for relapsing varied, but most were related to a
stressful event or time period, such as job loss or relationship problems. One participant explained, “You
know that saying ‘when it rains, it pours’? I just had a
bad day one day, from the time I got up until that evening, it was just a bad day with my grandchildren, my
children, my mom, everybody, and I just couldn’t take it
no more and I just ran out the door with 50-cents to
buy a cigarette.”
Perceptions about and experience with lung cancer
screening

When asked about lung cancer screening tests, participants had little to no awareness that such tests existed.
Data reflecting participants’ limited knowledge about
each specific test are provided below.
After the facilitator showed pictures of equipment
used during each type of screening test, participants
relayed general knowledge or experience with the test.
However, the experiences they described were often related to diagnostic procedures, not screening exams. For
example, when asked about lung cancer screening with
chest x-ray, one participant said, “Yeah… I had a real
bad cough and I guess [my doctor] said, ‘Go get a chest
x-ray.’” .
CT scans

Only two participants in the focus groups were aware
that CT scans could be used for lung cancer screening.
One learned about it from a diagnostic imaging center
representative: “He said if you smoke, even if you have
to pay for it out-of-pocket, a CAT scan will show early
detection.” Other participants described instances in
which lung abnormalities were detected by CT scan, but
the detection occurred as a result of a doctor ordering
the procedure for an unrelated condition. As one participant explained, “When I had my clot issue [in my
heart]… I got a CT scan but they found a spot on the
lower left lobe of my lung.” Others knew that a CT scan
could be used as a diagnostic procedure for a variety of
conditions. For example, one participant said, “I’ve heard
of [CT scan] being used when something is wrong

A small number of participants knew about chest x-rays
as a lung cancer screening test. Some said their doctor
regularly prescribed chest x-rays because of their smoking history: “When I was younger… [doctors] always referred me to get a chest x-ray at least once a year.”
Others said they were screened less frequently: “That’s a
chest x-ray. That’s the only [lung cancer screening test] I
know about. I get one every five years.” Regardless of the
frequency of the screening, participants understood that
chest x-rays lacked sensitivity as a screening test. One
participant suggested that a person had to be “practically
gone” with lung cancer for it to be detected by chest xray. Another said, “…the doctor told me if you was eat
up with cancer, it would show up on [chest x-ray], but
he said it’s not a good way to screen for it.” Another participant explained, “The only thing that I’ve heard [about
chest x-ray] is that if there is a mass it will show up, but
it’s not really a true test. I mean, it’s not a true
screening.”
In general, participants who had been screened with
chest x-rays recalled limited communication with their
doctors about the test and its effectiveness. As one participant remembered, “Well, basically… [chest x-ray]
really doesn’t show a whole lot. It would show maybe
some abnormalities. [The doctors] were very vague
about it.” Participants also recalled only limited communication about their results. One participant said, “I get
a letter two, three weeks later…with the results. I may
not necessarily know what they mean but I figure if [the
doctor’s] not calling me, then everything’s all right.”
Sputum cytology, Spirometry, and pulmonary function tests

No participant had heard of sputum cytology as a potential lung cancer screening test. However, some suggested
that doctors could screen for lung cancer by spirometry
(i.e., the doctor holds a stethoscope to the patient’s chest
and listens to him/her breathe) or by pulmonary function tests (i.e., the patient blows into a machine that
measures the volume and speed of air flow).
Desire to pursue lung cancer screening

Most participants learned about lung cancer screening
for the first time during the focus groups. As the discussions concluded, many participants expressed interest in
pursuing lung cancer screening. One participant said, “I
think I’m going to try to find out more about [lung
cancer] screening because I do smoke and I’m constantly
scared.” Other participants suggested that doctors
should redirect their patient education efforts from
smoking cessation to lung cancer screening: “At this
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point in my life, I want my doctor to say, ‘You know
what, you’ve been smoking these cigarettes. I want to
start doing this testing on you to make sure that cancer’s
not lurking somewhere.’” .
Some participants who had not previously heard about
lung cancer screening expressed frustration that their
doctors had not told them about it. One participant said,
“I’m thinking I’m going to ask my doctor why hasn’t
she not only offered [lung cancer screening] to me,
but at least given me the option, tell me what [lung
cancer screening tests] are and what they consist of
and what the benefits would be and let me make the
decision. Or even just to see if my insurance would
cover it. Because it’s something that I would love to
have done.”
Another participant suggested that doctors may purposely withhold information about lung cancer screening: “Maybe they just figure you deserve [lung cancer]
since you smoke.” As previously noted, participants were
told at the end of the focus groups that the USPSTF did
not recommend lung cancer screening at that time.
Perceived barriers to lung cancer screening

Although many participants expressed an interest in
lung cancer screening, others had concerns that could
be potential barriers to screening. We identified seven
barriers to screening at three levels of the social ecological model (Table 2): cost of procedure (CT specifically) and confusion around screening results at the
health care system level; fatalistic beliefs and distrust of
the medical system at the cultural level; and lack of
knowledge about screening, denial of risk for lung cancer, and concerns about the screening procedure at the
individual level. Table 2 provides illustrative quotes for
each barrier.

Discussion
This qualitative study found that smokers had limited
knowledge of lung cancer screening. Moreover, study
participants who were aware of lung cancer screening
most often described experiences with chest x-ray, a test
that has been shown to be ineffective for lung cancer
screening [12]. Only two of the 105 participants in our
study were familiar with the use of a CT scan for lung
cancer screening. The general lack of awareness of CT
scan as a screening test for lung cancer is consistent
with more recent qualitative research, indicating that
lack of knowledge may continue to be an issue for
screening uptake. [13, 14]. As screening with low-dose
CT becomes more available, research should continue to
assess whether eligible smokers are aware of the availability of screening. Although several states had few or
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no lung cancer screening centers shortly after the recommendations were released [15], the national landscape for lung cancer screening is likely to change in the
coming years [16].
Although most participants were unaware of lung cancer screening when the focus groups began, many
expressed an interest in pursuing it as an option. Nearly
all had tried to stop smoking at least once using a variety
of approaches, leading some to even suggest that cessation efforts be redirected toward screening. These sentiments reflect the need for doctors to communicate the
limitations of low-dose CT scans and the process and
risks associated with follow-up diagnostic testing. However, the participants who had experience with lung cancer screening tests recalled only limited communication
with their doctors about the procedure, echoing findings
of another study [17]. The 2015 CMS coverage decision
attempts to address this issue by requiring an initial visit
for counseling and shared decision making. Specifically,
it states that this visit should include the following: "1)
determination of beneficiary eligibility; 2) the use of one
or more decision aids, to include benefits and harms of
screening, follow-up diagnostic testing, over-diagnosis,
false positive rate, and total radiation exposure; 3) counseling on the importance of adherence to annual lung
cancer low-dose CT screening, impact of comorbidities
and ability or willingness to undergo diagnosis and treatment; and 4) counseling on the importance of maintaining cigarette smoking abstinence if former smoker; or
the importance of smoking cessation if current smoker
and, if appropriate, furnishing of information about tobacco cessation interventions…" [4]. The website of the
American College of Radiology includes sample forms
and other resources for meeting and documenting these
CMS requirements [18]. A recent study found that decision aids were indeed effective in increasing low income
patients’ understanding of the potential for false positives and extra testing associated with lung cancer
screening [19].
About two-thirds of our study participants were
smokers who would not meet the 2013 USPSTF or 2015
CMS eligibility criteria for screening. Their interest in
lung cancer screening suggests that doctors may need to
be prepared to respond to questions from both those
who meet the eligibility criteria for screening and those
who do not.
Despite the difficulties with quitting smoking that our
participants reported, smoking cessation remains the
most effective way to prevent lung cancer [20]. To ensure that cessation efforts are maintained as lung cancer
screening programs are implemented, researchers need
to understand how lung cancer screening test results affects smokers’ cessation attempts. According to a 2010
estimate, approximately 8.7 million current and former

Gressard et al. BMC Public Health (2017) 17:589

Page 6 of 8

Table 2 Perceived barriers to lung cancer screening and illustrative participant quotes, by social ecological model level
Health care system level barriers
Cost of procedure

“I actually scheduled [a screening] and then they called me back and told me I needed to bring $300 with me.
And I just didn’t have it for something that was not wrong with me.”
“Insurance, you know. More than likely unless there is something that calls for [a CT scan], to just to go in and
say you’d like to have one, on the safety side, insurance won’t pick it up.”
“The cost, yeah. [Doctors] don’t just say, ‘Oh, let’s go have a CAT scan to see if you got cancer.’”
“It probably comes from the insurance companies. Why should the doctor put you out that way because you
may end up having to pay for the test in the first place because you smoke. Insurance companies don’t want
to pay for anything.”

Confusion around test results

“A lot of times [screening tests] don’t really see things because like I just had a mammogram. Then they said,
‘We want you to go over here and get an ultrasound. Then we want you to go over here,’ you know.”
“…you have just put me through all this mind bending and tests and running all over the place. I’ve been a
stress mess. Tell me once and for all, do I have something or do I not? And I don’t believe that those tests can
do that.”

Cultural level barriers
Fatalistic beliefs

“It’s part of the fear of having it done and then finding out that you do have it [lung cancer]. I don’t know if
that’s true but everybody that I’ve come across, if they find out they have it then you’re going to have it in
your mind, ‘Oh, my God, I have it. I’m going to die.’”
“She said they thought they found, saw something…they wanted to run more tests. I just didn’t show back
up because I feel like if it’s my time, I don’t want to know about it.”
“[The CT]‘s the one I would feel comfortable with, but me, in general, I’m like what I don’t know won’t hurt me.”

Distrust in medical system

“I’m kind of like the person that thinks doctors and insurance companies are in cahoots anyway. And every
time you go to the doctor, it doesn’t matter what you go for, they want you to have this test. They want you
to have that test. They want you to be checked for this and that and I’ve done it for so many years. That’s
why I don’t do it anymore unless it’s just absolutely necessary.”
“I don’t trust [my doctor]…Mine’s the in and out, I’ll push you in, push you out, push you in, push you out….
He don’t got time for me. He don’t touch me….He won’t look at me. He prints out the [prescriptions] on a
laptop. They’re shot straight to CVS. I’m in and out.”
“It’s like if you’re not hurt in that area, it’s avoided…. You’re checking the blood and doing this and that,
but if you’re not hurting in that particular area of the body, they’re not going to ask you. It’s like they want
to spend less money on you as possible.”

Individual level barriers
Lack of knowledge

“...why haven’t we heard [about] it? I mean, in this age of the Internet and news, why is that something that’s
not [known]. There’s plenty of medical shows on [television].”

Denial of risk

“I’m concerned about [lung cancer] but I don’t think about it…who knows if cigarettes actually cause that
[cancer]? I mean, there’s a lot of people that have cancer that never smoked.”
“I’m just getting ready to turn 50 and I keep thinking that’s not going to happen ‘til I’m over 70 or 80…So
you just kind of, I guess, denial.”
“I don’t want to know nothing else. Don’t hear no rattle. Don’t hear no bad news. I’m fine.”

Fear of screening procedure

“…when I had [a CT] they had to give me something to calm me because that little tube was too much
enclosure….And I got claustrophobia.”
“…an X-ray is… so much more relaxed. I don’t like MRIs and CAT scans…I’d rather stand in front of an X-ray
machine any day.”

smokers in the United States would meet the NLST criteria for lung cancer screening with low-dose CT [21].
Using data from the NLST, one study reported that a
false positive screening result was associated with increased smoking cessation and less relapse among recent
quitters. Negative screening results, in contrast, were
not associated with greater relapse among long-term
former smokers [22].
Understanding smokers’ barriers to lung cancer
screening with low-dose CT can help to guide intervention efforts and increase appropriate screening. This

study used the social ecological model to identify several
potential barriers, which are described using participant
quotes in Table 2. Recent studies have similarly identified cost and distrust as barriers, but have also found
smoking stigma and inconvenience (e.g., scheduling and
transportation) to be issues [14]. Further research is
needed to determine if these barriers can be generalized
to the current US population eligible for screening. For
example, increased coverage of payment for lung cancer
screening through the 2015 CMS ruling may decrease
the relevance of cost as a barrier.
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Our study has at least four limitations. First, our findings are limited to participants from two US cities in
2009; smokers in other communities may have different
perceptions, and smokers’ perceptions may have changed following the 2013 USPSTF and 2015 CMS recommendations. Nevertheless, this study may serve as a
baseline for changes in smokers’ knowledge and experience. Second, our criteria to select focus group participants were different from the 2013 USPSTF and 2015
CMS eligibility criteria for lung cancer screening. For example, nearly one fifth of our participants had a < 30
pack-year smoking history. It is possible that these
smokers with a shorter smoking history would be less
aware of lung cancer screening than those who meet the
30 pack-year requirement. Third, although our study included a larger proportion of African Americans (39.0%)
than the NLST study (4.5%), our study design did not
allow examination of results by race or ethnicity [23].
Previous research suggests, however, that African
Americans are more likely than Whites to avoid screening due to fear of the disease [24]. This idea supports
the barrier related to fatalistic beliefs that was identified
in this study. Fourth, nearly two thirds of our study had
at least a college education, indicating that this group
was particularly highly educated. Nevertheless, the lack
of knowledge about lung cancer screening and the desire
to learn more has been similarly noted in qualitative
studies of low income, less educated patients [19].

Conclusion
Although the smokers in this study had little experience
with and knowledge about lung cancer screening, their
interest in exploring it as an option was clear. Implementation of lung cancer screening should include sufficient
education and tools to improve patient understanding of
the benefits and risks of screening. Additional qualitative
studies that examine smokers’ knowledge about lung cancer screening are also recommended as screening becomes more widely used in the United States. At the same
time, researchers and health care providers must continue
to make smoking cessation a priority because it is the
most effective way to prevent lung cancer.
Additional file
Additional file 1: Discussion Moderators’ Guide for Smokers. Description
of Data: Semi-structured moderator guide used to conduct focus groups
of smokers for this study. File Format: Adobe PDF (.pdf). (PDF 224 kb)
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